Organization
Hôpital Foch
5 abstracts
Abstract
The FIPO23 trial: First-in-human phase I/II study of XON7 in advanced solids tumors.Org: Hôpital Foch,
Abstract
Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).Org: Institut de Cancérologie Gustave Roussy, Université Paris-Saclay, Gustave Roussy, Villejuif, France, Yale School of Medicine, University of California Irvine, Centre Léon Bérard,
Abstract
Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.Org: Institut de Cancérologie Gustave Roussy, Villejuif, France, France, Perlmutter Cancer Center at NYU Langone Health Medical Center, New York, NY,
Abstract
Darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: Second interim analysis.Org: Fred Hutchinson Cancer Research Center, University of Washington and Fred Hutchinson Cancer Research Centre, Associated Medical Professionals of NY, Toho University Sakura Medical Center, First Urology,
Abstract
ANTI PM-SCL ASSOCIATED AUTO IMMUNE DISEASES: MULTICENTRIC COHORT OF 128 PATIENTSOrg: Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Centre de Référence pour les Maladies Auto-immunes Rares, Université de Paris, Médecine Interne, CHU Estaing, Clermont-Ferrand, France,